The patient-prediction layer for in-space drug development.
PROBE-Orbital reads live orbital biology as it happens and predicts how in-space-manufactured drugs will perform in real humans on Earth, one patient at a time.
Orbital biology, made clinically actionable for a specific human.
The 90% failure rate in clinical trials is driven by unmodeled patient heterogeneity and a broken translation path from microgravity science to prescribed medicine. PROBE-Orbital closes both gaps at once.
- Digital Patient Twin (DPT)
- A multi-omic computational model of a real patient that simulates how that individual human responds to a given drug or biologic.
- PROBE-Orbital
- The real-time patient-prediction software layer that integrates into a partner's live ISS biology experiment, ingests biomarker and imaging telemetry as it streams down, maps it to matched Digital Patient Twins, and returns per-patient drug-response predictions while the experiment is still running.
Two industries have never been connected. We are the connection.
Digital-twin firms predict patient response, but only on Earth, from historical data. Space-biology firms generate world-unique accelerated-disease data in orbit, yet have no patient-prediction layer. PROBE-Orbital is the analytical layer any space-biology experiment plugs into.
Orbital biology
Human disease tissue progresses through disease states in weeks under sustained microgravity, producing data that exists nowhere on Earth. Rich, accelerated, and today, unread at the patient level.
The real patient
A specific human with a multi-omic profile, waiting for a therapy that will actually work for them. PROBE turns the orbital signal into a prediction for that person.
A software demonstration flown in-the-loop with a live ISS investigation.
Infiuss flies software and a data interface. The biology payload is owned by our partner. Over a 35–45 day mission, the loop runs continuously.
Integrate
A PROBE data-interface module is co-located with the partner's biology cassette on the ISS and tied into the Implementation Partner's downlink, using standard data and power interfaces, no specialized life support, and automated operation with minimal crew time.
Ingest
As the microgravity experiment runs, PROBE captures live biomarker and imaging telemetry from accelerated disease tissue and relays it to ground under real ISS latency and downlink conditions.
Predict
Telemetry is mapped to matched Digital Patient Twins, which generate per-patient drug-response predictions in real time and in-the-loop, while the experiment is still progressing.
Validate
Predictions are compared against the experiment's observed tissue response, producing closed-loop, in-mission validation and a regulatory evidence package extending our PROCOVA methodology.
This capability cannot be validated by buying a dataset after the fact.
Weeks, not years
Accelerated-disease tissue progresses through disease states in weeks under sustained microgravity. Drop towers (seconds), parabolic flights (~25s), and suborbital vehicles (3–4 min) cannot sustain it.
Live, not archived
A static dataset shows what happened. It cannot prove PROBE can ingest live orbital telemetry and return predictions fast enough to inform in-mission decisions. That only exists in a real orbital experiment.
Evidence no one else has
Success yields the first in-mission patient-prediction validation against live orbital biology, a capability no competitor holds, plus refined models with regulatory evidence.
A prediction layer for an industry that has drawn ~$80B in a decade and yet has no incumbent building one.
The healthcare digital-twin market is projected to grow from ~$4B in 2024 to $35B+ by 2032, against ~$70B in annual clinical-trial spend where 9 in 10 candidates fail.
Annual pharma spend on ISS-related programs already exceeds $1B, projected to expand to $5–10B by 2032 as commercial stations come online, with biopharma the highest-value-per-kilogram application in orbit.
Conservative 5-year ARR from the space-biotech wedge alone: direct sponsor sales, CDMO white-label partners, and commercial-station platform contracts, all additive to the terrestrial pipeline.
PROBE-Orbital, in plain terms.
What is PROBE-Orbital?
PROBE-Orbital is the real-time patient-prediction software layer for in-space drug development, built by Infiuss Health. It integrates into a partner's live ISS biology experiment, ingests biomarker and imaging telemetry in real time, maps it to matched Digital Patient Twins, and produces per-patient drug-response predictions while the experiment runs.
What is a Digital Patient Twin?
A Digital Patient Twin (DPT) is a multi-omic computational model of a real patient that simulates how that individual human responds to a given drug or biologic. Infiuss Health has deployed 5,800 Digital Patient Twin models across 13 completed clinical studies.
Why does patient prediction for space drugs require the ISS?
Two things exist only in orbit. First, the accelerated biology: human disease tissue progresses through disease states in weeks under sustained microgravity, which short-duration platforms cannot sustain. Second, the live in-the-loop prediction: proving software can ingest real orbital telemetry under actual ISS latency and downlink conditions, and return predictions fast enough to inform in-mission decisions, can only be validated in a real orbital experiment.
How is PROBE-Orbital different from other digital-twin or space-biology companies?
Terrestrial digital-twin firms predict patient response but operate only on Earth from historical data. Space-biology firms generate world-unique accelerated-disease data in orbit but have no patient-prediction layer. PROBE-Orbital is the first system to connect the two, running patient-level predictions in-the-loop with a live orbital biology experiment rather than analyzing a dataset months later.
Who is PROBE-Orbital for?
It serves in-space biopharma sponsors who pay to have orbital experiment data translated into per-patient predictions; space-biology platforms and CDMOs that resell PROBE-enabled prediction with their offerings; and commercial LEO destinations that license PROBE as tenant-attraction infrastructure.
What is the technology readiness level?
Infiuss Health's terrestrial Digital Patient Twin engine is at TRL 8 and operating commercially today. The orbital-integration configuration, PROBE-Orbital, is at TRL 4, with a planned ISS software demonstration targeted for late 2027 to the first half of 2028 to advance it to TRL 6.
You spend $1M–$10M per flight. PROBE turns that data into per-patient decisions.
We're securing one biology partner and one pharma co-funder for the first flight. If you run an ISS investigation, or want to, let's talk.
Contact Infiuss Health →